The Indian Pharmaceutical Alliance is using Medsecurean to advance a closer relationship between India and the US, and investment opportunities for India’s drug companies.
Medsecurean will position the Indian pharmaceutical sector as a “critical US diversification supply solution and garner a seat at the table for the IPA on significant security and healthcare-pharmaceutical policy discussions,” according to the firm’s agreement.
The Great Falls, VA-based firm also will enhance IPA’s engagement with the US Food and Drug Administration with respect to foreign inspections and manufacturing innovation. India has the largest number of US FDA-approved facilities outside of the US.
Kathleen Jaeger heads Medsecurean. She is the former CEO of the Generic Pharmaceutical Association, and senior VP at the National Association of Chain Drug Stores.
Medsecurean’s one-year contract began Aug. 1 and is worth $120K.